VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

T. brucei DNA Vaccine encoding TSA protein T. brucei Subunit p15 Protein Vaccine
Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0011491
  • Type: DNA vaccine
  • Status: Research
  • TSA gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Vector: pVAX1 (Silva et al., 2009)
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0011492
  • Type: Subunit vaccine
  • Status: Research
  • MAPP15 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: complete Freunds adjuvant
  • Adjuvant: incomplete Freunds adjuvant
  • Immunization Route: Subcutaneous
Host Response Host Response

Mouse Response

  • Host Strain: BALB-c
  • Vaccination Protocol: Mice were immunized by injecting 100 μg (200 μl) of plasmid DNA encoding nTSA gene by intramuscular route. As a control groups, five mice were injected with 100 μg of plasmid pVAX1LacZ (Invitrogen—USA) and with 200 μl of PBS by the same route (Silva et al., 2009).
  • Challenge Protocol: After 175 days of immunization, mice in vaccinated and control groups were submitted to the challenge assay, performed by intraperitoneal injection of 500 parasites (T. b. brucei GVR 35 1.5) per animal. The period of survival, defined as the number of days after infection that the infected animals remain alive, was evaluated (Silva et al., 2009).
  • Efficacy: The DNA vaccination process was able to protect 60% of mice submitted to a challenge assay with the infective form of T. brucei brucei parasites (Silva et al., 2009).

Mouse Response

  • Host Strain: Swiss
  • Vaccination Protocol: Swiss male mice were injected three times subcutaneously on days 1, 7 and 21 with the antigen. Antigen contained 10 μg of native p15 isolated from T. brucei brucei KETRI 2693, recombinant p15 purified from Ad-p15 infected HEK293 cells, partially purified subpellicular microtubules as a positive control (subpellicular fraction >30 kDa), or with PIPES buffer used to purify p15 as a negative control. Vaccinations included complete Freund’s adjuvant on first injection and incomplete Freund’s adjuvant on second and third injections. To test the protective potential of the recombinant viral vaccine, mice were injected intramuscularly (on days 1, 7 and 21) with 2×109 Ad-p15 virus particles or with control Ad-lacZ (Rasooly and Balaban, 2004).
  • Challenge Protocol: Animals were challenged intraperitoneally on day 31 with 500 T. brucei brucei strain SB1 (Rasooly and Balaban, 2004).
  • Efficacy: Vaccination of mice with p15 (native or recombinant) generated up to 100% protection from an otherwise lethal challenge of a heterologous strain of Trypanosoma brucei (Rasooly and Balaban, 2004).
References References
Silva et al., 2009: Silva MS, Prazeres DM, Lança A, Atouguia J, Monteiro GA. Trans-sialidase from Trypanosoma brucei as a potential target for DNA vaccine development against African trypanosomiasis. Parasitology research. 2009; 105(5); 1223-1229. [PubMed: 19582478].
Rasooly and Balaban, 2004: Rasooly R, Balaban N. Trypanosome microtubule-associated protein p15 as a vaccine for the prevention of African sleeping sickness. Vaccine. 2004; 22(8); 1007-1015. [PubMed: 15161078].